Dehydroepiandrosterone (DHEA), Five Specimens
Use
Dehydroepiandrosterone (DHEA) measurement is used to evaluate adrenal gland function and to help diagnose adrenal gland tumors, and male hypogonadism. The five-specimen collection at multiple time points allows for monitoring changes in DHEA levels in response to a given treatment or medication, providing useful insight into the dynamic hormonal response.
Special Instructions
Refer to the Endocrine Appendix of the LabCorp Directory of Services for instructions on multiple specimen collection. This test requires an initial tube to be collected as a baseline. Subsequently, the patient undergoes treatment (e.g., medication or glucola) with further specimens collected post-treatment. Ensure coordination with the clinician to determine if this series panel is appropriate, based on whether a treatment is planned after the initial sample.
Limitations
This test has not been cleared or approved by the FDA. The performance of this test is based on LabCorp's internal validation studies. Results should be interpreted in the context of the complete clinical picture alongside other diagnostic tests. The reference intervals for DHEA levels may not be established beyond the baseline specimen, as levels can vary after treatment.
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 2193-1
- 46963-5
- 12590-6
- 12591-4
- 12592-2
- 12593-0
Result Turnaround Time
4-6 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Multiple tubes
Minimum Volume
Not provided
Container
Standard serum tubes
Collection Instructions
Collect the initial tube as a baseline. Administer drug or treatment, then collect subsequent tubes at prescribed intervals.
Patient Preparation
Ensure the patient has consulted their clinician to confirm that a treatment will follow the initial sample draw.
Causes for Rejection
Improperly labeled specimens or insufficient volume.